Literature DB >> 16026650

Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin.

Ardith W El-Kareh1, Timothy W Secomb.   

Abstract

A mathematical model is presented for the cellular uptake and cytotoxicity of the anticancer drug doxorubicin. The model assumes sigmoidal, Hill-type dependence of cell survival on drug-induced damage. Experimental evidence indicates distinct intracellular and extracellular mechanisms of doxorubicin cytotoxicity. Drug-induced damage is therefore expressed as the sum of two terms, representing the peak values over time of concentrations of intracellular and extracellular drugs. Dependence of cell kill on peak values of concentration rather than on an integral over time is consistent with observations that dose-response curves for doxorubicin converge to a single curve as exposure time is increased. Drug uptake by cells is assumed to include both saturable and unsaturable components, consistent with experimental data. Overall, the model provides better fits to in vitro cytotoxicity data than previous models. It shows how saturation of cellular uptake or binding with concentration can result in plateaus in the dose-response curve at high concentrations and short exposure, as observed experimentally in some cases. The model provides a unified framework for analyzing doxorubicin cellular pharmacokinetic and pharmacodynamic data, and can be applied in mathematical models for tumor response and treatment optimization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026650      PMCID: PMC1501422          DOI: 10.1593/neo.05118

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  27 in total

1.  A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect.

Authors:  N J Millenbaugh; M G Wientjes; J L Au
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

2.  High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer.

Authors:  M E Lippman
Journal:  N Engl J Med       Date:  2000-04-13       Impact factor: 91.245

3.  Modeling of the time-dependency of in vitro drug cytotoxicity and resistance.

Authors:  L M Levasseur; H K Slocum; Y M Rustum; W R Greco
Journal:  Cancer Res       Date:  1998-12-15       Impact factor: 12.701

4.  Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention.

Authors:  J L Au; D Li; Y Gan; X Gao; A L Johnson; J Johnston; N J Millenbaugh; S H Jang; H J Kuh; C T Chen; M G Wientjes
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

5.  In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols.

Authors:  K H Link; G Leder; J Pillasch; U Butzer; L Staib; M Kornmann; U Bruckner; H G Beger
Journal:  Semin Surg Oncol       Date:  1998 Apr-May

6.  A mathematical model of cancer chemotherapy with an optimal selection of parameters.

Authors:  R B Martin; M E Fisher; R F Minchin; K L Teo
Journal:  Math Biosci       Date:  1990-05       Impact factor: 2.144

7.  A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs.

Authors:  S N Gardner
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

Review 8.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.

Authors:  D A Gewirtz
Journal:  Biochem Pharmacol       Date:  1999-04-01       Impact factor: 5.858

9.  Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.

Authors:  A Iliadis; D Barbolosi
Journal:  Comput Biomed Res       Date:  2000-06

10.  Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin.

Authors:  K Nagasawa; T Natazuka; M Nomiyama; N Ohnishi; T Yokoyama
Journal:  Biol Pharm Bull       Date:  1996-01       Impact factor: 2.233

View more
  43 in total

1.  Targeted drug delivery by high intensity focused ultrasound mediated hyperthermia combined with temperature-sensitive liposomes: computational modelling and preliminary in vivovalidation.

Authors:  Astrid Gasselhuber; Matthew R Dreher; Ari Partanen; Pavel S Yarmolenko; David Woods; Bradford J Wood; Dieter Haemmerich
Journal:  Int J Hyperthermia       Date:  2012       Impact factor: 3.914

2.  Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation.

Authors:  Astrid Gasselhuber; Matthew R Dreher; Ayele Negussie; Bradford J Wood; Frank Rattay; Dieter Haemmerich
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 3.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

4.  A new mathematical pharmacodynamic model of clonogenic cancer cell death by doxorubicin.

Authors:  Jan Lankelma; Rafael Fernández Luque; Henk Dekker; Jaap van den Berg; Bob Kooi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-07-18       Impact factor: 2.745

5.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

6.  Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours.

Authors:  Pavel S Yarmolenko; Yulin Zhao; Chelsea Landon; Ivan Spasojevic; Fan Yuan; David Needham; Benjamin L Viglianti; Mark W Dewhirst
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

7.  Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel.

Authors:  Hua He; Yanguang Cao
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-08-31       Impact factor: 2.745

8.  A tumor cord model for doxorubicin delivery and dose optimization in solid tumors.

Authors:  Steffen Eikenberry
Journal:  Theor Biol Med Model       Date:  2009-08-09       Impact factor: 2.432

9.  Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation.

Authors:  John P Sinek; Sandeep Sanga; Xiaoming Zheng; Hermann B Frieboes; Mauro Ferrari; Vittorio Cristini
Journal:  J Math Biol       Date:  2008-09-10       Impact factor: 2.259

10.  The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.

Authors:  Krupa J Patel; Ian F Tannock
Journal:  BMC Cancer       Date:  2009-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.